MarketCap
Facebook
X
Telegram
Johnson & Johnson ROCE Ratio | JNJ
Annual ROCE Ratio Johnson & Johnson
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 14.23 | 14.79 | 17.23 | 18.17 | - | 19.39 | 14.46 | 13.61 | 21.23 | 32.78 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32.78 | 13.61 | 18.43 |
Quarterly ROCE Ratio Johnson & Johnson
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 27.12 | 35.22 | 26.64 | 31.86 | 28.53 | 26.16 | 18.06 | 23.96 | 22.83 | 23.96 | 17.91 | 25.47 | 25.26 | 29.06 | 21.15 | 7.56 | 5.69 | 7.89 | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 35.22 | 5.69 | 25.7 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
289.47 | - | - | $ 24.9 M |  USA |
 |
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-175.6 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-29.63 | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
-165.18 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
74.33 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-41.99 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-71.67 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-102.25 | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
-461.01 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-67.97 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
-1.91 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
14.56 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-35.74 | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
49.6 | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
35.76 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-14.94 | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
44.14 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
6.19 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
14.33 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
-43.45 | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
-197.97 | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
-69.43 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-186.76 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-82.2 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
-95.03 | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-377.18 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-53.64 | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-108.97 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-52.09 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-25.13 | $ 0.39 | 0.15 % | $ 1.91 M | USA |
 |
TFF Pharmaceuticals
TFFP
|
-228.86 | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
-13.2 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
-3.47 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-580.3 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-13.43 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-82.6 | $ 1.09 | 6.37 % | $ 95 M | USA |
 |
MannKind Corporation
MNKD
|
6.25 | $ 3.91 | 4.0 % | $ 1.2 B | USA |
 |
MediciNova
MNOV
|
-31.94 | $ 1.44 | -0.69 % | $ 70.7 M | USA |
 |
Axcella Health
AXLA
|
-1848.9 | - | -16.42 % | $ 249 M | USA |
 |
Merck & Co.
MRK
|
19.69 | $ 146.81 | -0.07 % | $ 367 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-0.69 | - | - | $ 2.02 B | USA |
 |
Tyme Technologies
TYME
|
-31.86 | - | 8.07 % | $ 54 M | USA |
 |
Curis
CRIS
|
-104.6 | $ 0.88 | 3.67 % | $ 11.6 M | USA |